Dxs has entered a partnership with Altheadx to provide its K-Ras mutation detection assays to US study centres.
Altheadx will use Dxs's K-Ras Mutation Test Kits to assess the K-Ras mutation status of cancer patients.
David Macdonald, chief executive officer of Altheadx, said: 'The Dxs kit will enable Altheadx to offer K-Ras analysis for future clinical trials to further advance the developments that have seen patients being prescribed the appropriate targeted cancer based on their genetic profile.' The Dxs K-Ras Mutation Test Kit allows clinicians to screen patients for mutations in the K-Ras gene, which is mutated in approximately 35-45 per cent of metastatic colorectal cancer and many other cancers.
New findings have revealed the most appropriate treatment for colorectal cancer patients can only be identified once they have been screened for mutations in the K-Ras gene.
Patients carrying mutations in the K-Ras gene do not respond to a class of drugs known as EGFR inhibitors, which includes Vectibix and Erbitux.
